Bicara Therapeutics Inc. Common Stock (NASDAQ: BCAX) is a Healthcare company (Biotechnology) with a market capitalization of $572M. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Bicara Therapeutics Inc. Common Stock had a Maz Rating of 4.41 out of 5 (A, Strong Buy), ranked against the other companies in its sector. Its strongest factor then was Momentum (4.71), among the strongest in its sector; its weakest was Valuation (2.15), more expensive than most of its sector. The other factors: Financial Health 4.22 (above most of its sector); Growth 3.30 (around the middle of its sector); Profitability 2.40 (below most of its sector). The current rating is for members: log in to see it.
At $8.65, Bicara Therapeutics Inc. Common Stock trades at 1.3x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -41.5%, return on invested capital of -43.0% and a free cash flow yield of -23.6%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 11.59. Over the past 52 weeks the share price ranged from $7.87 to $30.99, with a beta of -0.82.
Bicara Therapeutics Inc. Common Stock does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 6 Buy, 2 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.